Please use this identifier to cite or link to this item: https://doi.org/10.1002/cti2.1403
Title: Heterologous booster vaccination with CoronaVac following prime vaccination with mRNA vaccine
Authors: Goh, Yun Shan
Fong, Siew-Wai 
Rouers, Angeline
Chang, Zi Wei
Tay, Matthew Zirui
Chavatte, Jean-Marc
Zhuo, Nicole Ziyi
Hor, Pei Xiang
Loh, Chiew Yee 
Huang, Yuling
Wong, Joel Xu En
Tan, Yong Jie
Lim, Daniel Rui Xiang 
Wang, Bei 
Ngoh, Eve Zi Xian
Salleh, Siti Nazihah Mohd
Lee, Raphael Tze Chuen
Pada, Surinder 
Sun, Louisa Jin
Ong, Desmond Luan Seng 
Somani, Jyoti 
Lee, Eng Sing
Maurer-Stroh, Sebastian 
Wang, Cheng-I
Leo, Yee-Sin 
Lin, Raymond TP
Ren, Ee Chee 
Lye, David C
Young, Barnaby Edward
Lim, Poh Lian 
Ng, Lisa FP
Renia, Laurent 
Keywords: Science & Technology
Life Sciences & Biomedicine
Immunology
Allergic
Antibodies
B cells
CoronaVac
COVID-19
Delta
Omicron
S protein
SARS-CoV-2
T cells
BNT162B2
IMMUNOGENICITY
Issue Date: 1-Jan-2022
Publisher: WILEY
Citation: Goh, Yun Shan, Fong, Siew-Wai, Rouers, Angeline, Chang, Zi Wei, Tay, Matthew Zirui, Chavatte, Jean-Marc, Zhuo, Nicole Ziyi, Hor, Pei Xiang, Loh, Chiew Yee, Huang, Yuling, Wong, Joel Xu En, Tan, Yong Jie, Lim, Daniel Rui Xiang, Wang, Bei, Ngoh, Eve Zi Xian, Salleh, Siti Nazihah Mohd, Lee, Raphael Tze Chuen, Pada, Surinder, Sun, Louisa Jin, Ong, Desmond Luan Seng, Somani, Jyoti, Lee, Eng Sing, Maurer-Stroh, Sebastian, Wang, Cheng-I, Leo, Yee-Sin, Lin, Raymond TP, Ren, Ee Chee, Lye, David C, Young, Barnaby Edward, Lim, Poh Lian, Ng, Lisa FP, Renia, Laurent (2022-01-01). Heterologous booster vaccination with CoronaVac following prime vaccination with mRNA vaccine. CLINICAL & TRANSLATIONAL IMMUNOLOGY 11 (8). ScholarBank@NUS Repository. https://doi.org/10.1002/cti2.1403
Abstract: Objective: Despite the high vaccine efficacy of mRNA COVID-19 vaccines, there are individuals who developed excessive reactogenic and/or allergic responses after the first mRNA dose and were considered ineligible for further mRNA doses. CoronaVac, an inactivated SARS-CoV-2 vaccine, is recommended in Singapore as an alternative. Methods: Individuals, ineligible for further mRNA vaccines (BNT162b2 or mRNA-1273) because of excessive reactive responses to prime mRNA vaccination, were recruited and offered two doses of CoronaVac as booster vaccination 38–224 days post their mRNA vaccine dose. Individuals who did not develop any excessive reactive responses after the prime mRNA vaccination were also recruited and given another mRNA vaccine as booster vaccination. Blood samples were collected at days 0, 21 and 90 post first CoronaVac dose and mRNA dose, respectively, for analysis. Results: We showed that two CoronaVac booster doses induced specific immunity in these mRNA vaccine-primed individuals. Although the spike-specific antibody response was lower, their memory B cell response against the receptor-binding domain (RBD) of the spike protein was similar, compared with individuals who received two BNT162b2 injections. The spike-specific memory T cell response also increased following CoronaVac booster doses. However, specific immunity against the Omicron variant was low, similar to individuals with two BNT162b2 doses. Conclusion: Our findings showed that while mRNA vaccine-primed individuals can opt for two subsequent doses of CoronaVac, an additional dose may be necessary to achieve protection, especially against newly emerging immune escape variants such as Omicron.
Source Title: CLINICAL & TRANSLATIONAL IMMUNOLOGY
URI: https://scholarbank.nus.edu.sg/handle/10635/234734
ISSN: 2050-0068
DOI: 10.1002/cti2.1403
Appears in Collections:Staff Publications
Elements

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
Heterologous booster vaccination with CoronaVac following prime vaccination with mRNA vaccine.pdf2.29 MBAdobe PDF

OPEN

NoneView/Download

Page view(s)

13
checked on Dec 1, 2022

Download(s)

1
checked on Dec 1, 2022

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.